Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/15870435/ below:

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

Clinical Trial

Affiliations

• ¹ University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA.

• PMID: 15870435
• DOI: 10.1093/jnci/dji112

Item in Clipboard

Clinical Trial

Federico Cappuzzo et al. J Natl Cancer Inst. 2005.

• ¹ University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA.

• PMID: 15870435
• DOI: 10.1093/jnci/dji112

Item in Clipboard

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC.

Methods: Tumors from 102 NSCLC patients treated daily with 250 mg of gefitinib were evaluated for EGFR status by fluorescence in situ hybridization (FISH), DNA sequencing, and immunohistochemistry and for Akt activation status (phospho-Akt [P-Akt]) by immunohistochemistry. Time to progression, overall survival, and 95% confidence intervals (CIs) were calculated and evaluated by the Kaplan-Meier method; groups were compared using the log-rank test. Risk factors associated with survival were evaluated using Cox proportional hazards regression modeling and multivariable analysis. All statistical tests were two-sided.

Results: Amplification or high polysomy of the EGFR gene (seen in 33 of 102 patients) and high protein expression (seen in 58 of 98 patients) were statistically significantly associated with better response (36% versus 3%, mean difference = 34%, 95% CI = 16.6 to 50.3; P<.001), disease control rate (67% versus 26%, mean difference = 40.6%, 95% CI = 21.5 to 59.7; P<.001), time to progression (9.0 versus 2.5 months, mean difference = 6.5 months, 95% CI = 2.8 to 10.3; P<.001), and survival (18.7 versus 7.0 months, mean difference = 11.7 months, 95% CI = 2.1 to 21.4; P = .03). EGFR mutations (seen in 15 of 89 patients) were also statistically significantly related to response and time to progression, but the association with survival was not statistically significant, and 40% of the patients with mutation had progressive disease. In multivariable analysis, only high EGFR gene copy number remained statistically significantly associated with better survival (hazard ratio = 0.44, 95% CI = 0.23 to 0.82). Independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P-Akt-, or EGFR+/P-Akt- patients.

Conclusions: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC.

PubMed Disclaimer

• For EGFR research, new targeted drugs mean new questions.

  Vastag B. Vastag B. J Natl Cancer Inst. 2005 May 4;97(9):628-30. doi: 10.1093/jnci/97.9.628. J Natl Cancer Inst. 2005. PMID: 15870431 No abstract available.

• Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.

• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Douillard JY, et al. J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038723 Clinical Trial.

• A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?

  Kaye FJ. Kaye FJ. J Natl Cancer Inst. 2005 May 4;97(9):621-3. doi: 10.1093/jnci/dji127. J Natl Cancer Inst. 2005. PMID: 15870427 No abstract available.

• EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.

  Zhang X, Zhang Y, Tang H, He J. Zhang X, et al. J Investig Med. 2017 Jan;65(1):72-81. doi: 10.1136/jim-2016-000252. Epub 2016 Sep 23. J Investig Med. 2017. PMID: 27664271 Review.

• Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer.

  Hirsch FR, Witta S. Hirsch FR, et al. Curr Opin Oncol. 2005 Mar;17(2):118-22. doi: 10.1097/01.cco.0000155059.39733.9d. Curr Opin Oncol. 2005. PMID: 15725915 Review.

• EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.

  Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. Jung M, et al. Yonsei Med J. 2012 Nov 1;53(6):1128-35. doi: 10.3349/ymj.2012.53.6.1128. Yonsei Med J. 2012. PMID: 23074112 Free PMC article.

• Characterisation of the Expression of Neurotensin and Its Receptors in Human Colorectal Cancer and Its Clinical Implications.

  Qiu S, Nikolaou S, Zhu J, Jeffery P, Goldin R, Kinross J, Alexander JL, Rasheed S, Tekkis P, Kontovounisios C. Qiu S, et al. Biomolecules. 2020 Aug 5;10(8):1145. doi: 10.3390/biom10081145. Biomolecules. 2020. PMID: 32764278 Free PMC article.

• Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

  Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Hanna NH, et al. Cancer. 2015 Jul 1;121(13):2253-61. doi: 10.1002/cncr.29308. Epub 2015 Mar 4. Cancer. 2015. PMID: 25740387 Free PMC article. Clinical Trial.

• Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

  Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y, Shi H, Xie X, Wei W. Lv N, et al. Diagn Pathol. 2011 Dec 2;6:118. doi: 10.1186/1746-1596-6-118. Diagn Pathol. 2011. PMID: 22132735 Free PMC article.

• MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).

  Casadevall D, Gimeno J, Clavé S, Taus Á, Pijuan L, Arumí M, Lorenzo M, Menéndez S, Cañadas I, Albanell J, Serrano S, Espinet B, Salido M, Arriola E. Casadevall D, et al. Oncotarget. 2015 Jun 30;6(18):16215-26. doi: 10.18632/oncotarget.3976. Oncotarget. 2015. PMID: 26041880 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3